omeros stock — OMER Overview

Omeros stock (OMER) — Overview

omeros stock refers to shares of Omeros Corporation traded on the Nasdaq under the ticker OMER. This article focuses on Omeros as a publicly traded security: its listing and identifiers, market data and trading metrics, financial profile, drug pipeline and commercial prospects, recent regulatory and corporate events, analyst coverage and sentiment drivers, shareholder structure, trading characteristics (including options and short interest), governance and investor relations resources, principal risks, and practical ways to track OMER in real time. Readers will learn where to find live quotes and filings and how to interpret common market fields — plus practical suggestions to use Bitget for trading and Bitget Wallet for web3 needs when relevant.

Company profile

Omeros Corporation is a clinical-stage biopharmaceutical company focused on developing small-molecule and protein therapeutics for inflammatory, immune, hematologic and central nervous system disorders. Founded in the late 1990s and headquartered in Seattle, Washington, Omeros pursues a pipeline strategy centered on targeted biologics and novel mechanisms of action. As of the latest reporting, the company is led by a chief executive officer with senior management experienced in biotech development and commercialization.

The company’s science centers on complement, MASP-2 inhibition and other immune-modulating approaches across rare and severe disease indications. Omeros’ pipeline historically included lead assets such as narsoplimab (also known as OMS721) and other preclinical or clinical-stage candidates. The company combines in-house development with selective partnerships and licensing arrangements to advance programs through clinical proof-of-concept and potential commercialization.

Ticker and listing information

Omeros is listed on the Nasdaq Stock Market under the ticker symbol OMER. The company’s common shares trade in U.S. dollars and are identified by market identifiers such as the ISIN assigned to its equity class. Investors can obtain real-time or delayed quotes via major market data providers, brokerage platforms and the company’s investor relations pages.

How to read a basic quote for omeros stock:

• Last / Price: Most recent transaction price (real-time or delayed).
• Bid / Ask: Highest current buyer price and lowest current seller price; the spread indicates immediacy and liquidity.
• Volume: Number of shares traded in the trading session; average volume gives context for day-to-day liquidity.
• Market Cap: Price multiplied by shares outstanding — a quick gauge of company scale (time-sensitive).
• 52-Week High / Low: Range over the prior 52 weeks used to assess historical volatility and trading range.

For execution and custody, retail and institutional investors commonly use regulated brokerages and trading venues; for active traders seeking spot market access or margin, consider reputable platforms such as Bitget for order execution and market access. For research-only needs, major financial data providers and the company’s investor relations materials provide official quotes, press releases and filings.

Market data and key trading metrics

Investors commonly examine the following market-data items for omeros stock when making trading or monitoring decisions. Note that all numeric values below are time-sensitive — obtain the latest figures from live market feeds or official filings.

• Current and historical share price: Use intraday charts for short-term moves and weekly/monthly charts for trend context.
• Market capitalization: Snapshot of total equity value (price × shares outstanding).
• Shares outstanding and float: Total issued shares and freely tradable float; important for dilution and liquidity assessment.
• Average daily volume (ADV): Typical liquidity measured as average shares traded over 30/60/90-day windows.
• Bid/ask spreads and depth: Narrow spreads and depth indicate smoother execution; wide spreads reflect lower liquidity and higher execution cost.
• 52‑week high/low: Contextualizes recent price extremes.
• Basic valuation metrics: While many biotech companies are pre-profit, investors may look at enterprise value, price-to-sales (if revenue exists), cash per share and other adjusted metrics.

As of 2026-01-26, per company investor materials and market-data providers, omeros stock remains a small- to mid-cap biotechnology equity with typical trading volumes and volatility seen in clinical-stage biopharma names. Exact numeric metrics (market cap, ADV, shares outstanding) change daily; retrieve live numbers from Nasdaq quotes, major financial portals and your brokerage — or trade on Bitget for market access.

Financial summary

Biotech companies like Omeros often show revenue profiles that depend on licensing deals, royalties or potential product sales if a program receives approval. Key financial statement items for review include:

• Revenue: Historical revenue may be limited and lumpy; revenue drivers include collaborations, milestone payments and any product sales.
• Net income (loss): Clinical-stage biotechs commonly report recurring net losses driven by R&D and SG&A expenses.
• Cash and liquidity: Cash, cash equivalents and short-term investments indicate runway for ongoing trials; burn rate analysis shows operating runway absent new financing.
• Debt and capital structure: Convertible notes, term loans, and other debt instruments can influence dilution and capital flexibility.
• Recent quarterly results: Quarterly 10-Q filings and earnings releases summarize recent operational performance, cash position and management commentary.
• Key financial ratios and per-share metrics: Cash per share, operating expense run rate, and adjusted operating metrics provide helpful context.

Where to find details: the company’s SEC filings (10-K, 10-Q), investor presentations and earnings releases contain audited or management-level financial data. As of 2026-01-26, check Omeros’ most recent 10-Q or 10-K for precise figures on revenue, net loss, cash balance and outstanding debt. All financial figures are time-sensitive and should be verified in the primary filings.

Business operations and pipeline

Main programs and product candidates

Omeros’ pipeline historically focused on protein therapeutics and small molecules targeting complement pathways and other immune-mediated mechanisms. Principal programs have included narsoplimab (OMS721), a monoclonal antibody directed at MASP-2 (mannan-binding lectin-associated serine protease 2), developed for thrombotic microangiopathies and other severe indications. Other programs have involved additional immunology and hematology targets at various development stages, from preclinical through Phase II/III.

When evaluating omeros stock, investors typically review each program’s indication, mechanism of action, clinical-stage (preclinical, Phase I/II/III), trial endpoints, and any available efficacy/safety data from published studies or registrational submissions. Regulatory designation (e.g., Orphan Drug, Fast Track) can materially affect commercial potential and timelines.

Commercialization and partnerships

Commercialization status varies by program. Some assets may be in late-stage development or in discussions for market access, while others remain early-stage. Omeros has historically engaged in licensing or collaboration agreements to broaden development resources or to achieve geographic commercialization footprints. Partnership terms — including milestone payments, royalties and territory rights — significantly affect future revenue prospects.

Investors should examine any announced licensing deals, asset sales or commercialization agreements in press releases and SEC filings to understand revenue-sharing, milestone schedules and potential dilution from contingent considerations.

Recent developments, regulatory & corporate events

Material events that impact omeros stock include regulatory submissions, approval decisions, PDUFA or advisory committee dates, clinical data readouts, major press releases, licensing transactions, financings, and changes in management. Below is an example format for how to capture these events; replace placeholder entries with the latest dates from the company’s news feed and SEC filings.

• As of 2026-01-26, per Omeros investor relations, the company announced updates to its clinical development plan for lead assets and provided cash runway guidance tied to current programs and potential milestones.
• As of 2025-11-10, per a company press release, Omeros reported a late-stage clinical data readout for a key indication — see the company’s presentation slides and conference call transcript for detail.
• As of 2025-06-01, the company completed a financing transaction to strengthen liquidity, as disclosed in an 8-K and referenced in its most recent 10-Q.

For an investor, the timing and nature of these catalysts are crucial because biotech equities often react sharply to binary, program-specific outcomes. Always verify event dates and read the primary disclosure documents before drawing conclusions.

Analyst coverage and market sentiment

Analyst coverage for biotechnology stocks varies with company prominence and near-term catalysts. For omeros stock, coverage may include sell-side equity research notes, price-target updates, and initiation or reiteration of ratings by independent analysts. Consensus ratings and median price targets are compiled by data aggregators and research platforms.

Market sentiment also arises from retail and institutional flows, social and community platforms, and news-driven trading. Community platforms and stock-specific message boards can amplify short-term moves; investors should differentiate between data-driven analysis and sentiment-driven speculation. For active traders, short-term sentiment and newsflow can be as influential as fundamental developments.

Shareholder structure and insider / institutional ownership

Ownership in omeros stock typically falls into three buckets: insiders (executive officers and directors), institutional holders (mutual funds, ETFs, hedge funds), and retail investors. Institutional ownership levels and concentration among a few holders can affect liquidity and stock stability, while insider ownership levels provide context on management alignment with shareholders.

Key items to check:

• Top institutional holders and their share percentages — reported in 13F filings and data aggregators.
• Insider ownership percentage and any recent insider purchases or sales (reported via Form 4 filings).
• Float size relative to shares outstanding — a small float with concentrated institutional positions can increase price sensitivity to flows.

As with other data points, ownership metrics change over time; check the company’s latest proxy statement (DEF 14A) and institutional reporting feeds for up-to-date information.

Trading characteristics, options and short interest

Typical trading profiles for clinical-stage biotech stocks include elevated volatility around trial readouts, regulatory dates and corporate announcements. For omeros stock, investors often monitor:

• Volatility: Measure via historical volatility and implied volatility in options markets.
• Average daily volume: Higher volume improves execution and reduces slippage; low volume increases risk of price gaps and wide spreads.
• Options market activity: Presence of listed options allows hedging and advanced strategies; open interest and unusual activity can indicate positioning.
• Short interest and short ratio: Elevated short interest (shares sold short relative to float) can increase the potential for squeeze dynamics, particularly around positive catalysts.

Historical episodes of trading speculation may occur in response to clinical readouts or news; such moves are often transient and driven by market structure rather than fundamentals. For traders seeking options access or active margin trading, platforms like Bitget that list equities and derivatives (where available and regulated) may offer execution tools and order types to manage risk.

Corporate governance and investor relations

Governance documents, board composition, committee charters and executive compensation disclosures are all available in the company’s SEC filings and investor relations materials. Key investor relations resources include quarterly earnings releases, investor presentations, annual reports, and archived conference call transcripts.

Where to contact investor relations: the company’s investor relations team provides official press releases, financial reports and contacts for investor inquiries. For formal filings and governance documentation, consult the SEC EDGAR database for 10-Ks, 10-Qs, 8-Ks and proxy statements.

Risks and investment considerations

Investors should consider the following risks when assessing omeros stock. This list is factual, not exhaustive, and is not investment advice:

• Clinical and regulatory risk: Trial failures, safety signals, or unfavorable regulatory decisions can materially affect valuation.
• Binary catalysts: Many biotech programs are binary — a single trial outcome or approval decision can cause large price moves.
• Financing and dilution risk: Ongoing R&D often requires capital raises through equity issuances, convertible notes or strategic partnerships, which can dilute existing shareholders.
• Market and liquidity risk: Lower daily volume and a small float can amplify price swings and execution costs.
• Operational risk: Manufacturing, supply chain, and commercialization execution challenges can affect timelines and revenue capture.
• Competition and intellectual property: Competing therapies and patent disputes may impact market potential.

Historical performance and notable corporate actions

Historical corporate events that shape a biotech company’s market footprint include major financings, licensing deals, asset sales, convertible debt issuances, management changes, and regulatory milestones. For omeros stock, notable past actions to review in the company’s filings and press releases include:

• Major capital raises or convertible note issuances that altered the company’s capital structure and cash runway.
• Licensing or collaboration agreements that provided non-dilutive funding or regional commercialization partners.
• Regulatory submissions, advisory committee interactions and any product approvals or denials.
• Asset divestitures or acquisitions that materially changed the corporate strategy or cash position.

To build a chronology, compile dates and documents from the company’s press release archive and 8-K disclosures; these primary sources provide the most authoritative record of material actions.

How to track OMER (data sources)

For the most up-to-date and verifiable information on omeros stock, consult the following categories of sources. Note: do not rely solely on social media for material decision-making.

• Company investor relations: Official press releases, investor presentations and event transcripts provide primary disclosures and management commentary.
• SEC filings (EDGAR): 10-K, 10-Q, 8-K, DEF 14A and Form 4 filings are authoritative sources for financial statements, governance information and insider transactions.
• Market-data providers: Real-time quotes, charts and historical price data are available from major financial portals and brokerage platforms. For execution and trading, consider using Bitget’s market services for order placement and charting tools.
• Analyst research aggregators: Consensus ratings, price-target distributions and research notes are available through financial-data aggregators and institutional research terminals.
• News feeds and industry publications: Biotech-focused news outlets cover clinical readouts, regulatory filings and industry developments impacting price action.

As of 2026-01-26, per the company’s investor relations and filings, investors should monitor upcoming clinical milestones and any planned financing or partnership announcements. Always cross-check dates and figures with the company’s 8-K filings and conference call transcripts for accuracy.

References and external links

The following sources are routinely used to compile this kind of investor overview. For verification, consult the named sources directly and the primary filings referenced above. No external hyperlinks are included here by design; use the source names to search official sites and data providers.

• Omeros investor relations and press release archive (company disclosures)
• SEC filings via the EDGAR database (10-Q, 10-K, 8-K, Form 4, DEF 14A)
• Nasdaq market data and OMER quote pages
• Major financial data providers (example sources include Yahoo Finance, TradingView, Barchart, Finviz)
• Community and sentiment platforms (for market sentiment monitoring, e.g., StockTwits)
• Company presentations, clinical trial registries and peer-reviewed publications for program-level data

Appendix — Key documents to consult

• Latest Form 10-Q (quarterly report) for interim financials and liquidity disclosures.
• Latest Form 10-K (annual report) for comprehensive financial statements and risk factors.
• Most recent 8-K filings for material events and corporate transactions.
• Recent investor presentation slides and earnings call transcripts for management commentary.
• Clinical study publications, registrational documents and FDA correspondence for program-specific detail.

Practical next steps for readers

If you follow omeros stock, consider these practical actions:

• Set up real-time alerts from your preferred market data provider or brokerage for price moves, volume spikes and company press releases.
• Monitor upcoming clinical readouts and regulatory dates published by the company and clinical trial registries.
• Review the latest SEC filings (10-Q/10-K/8-K) before or after major announcements to verify facts and financial impact.
• For trading execution, consider Bitget for order placement and market tools; for web3 wallet needs, consider Bitget Wallet where appropriate.

Further reading and document review will deepen understanding of the scientific rationale, commercial potential and capital requirements that underpin omeros stock’s market valuation.

Disclosure

This article is informational and neutral. It does not constitute investment advice, solicitation or a recommendation to buy or sell securities. All factual statements are based on company disclosures and public market information as of the reporting dates noted. Verify real-time quotes and filings via the primary sources described above.

As of 2026-01-26, reported information in this piece referenced company investor materials and public market data providers for framing purposes; numerical market metrics are time-sensitive and should be checked against live feeds and SEC filings before acting.

Explore the market and research tools offered by Bitget to track live quotes, place orders, and manage positions in equities where available. For web3 and digital-asset wallet functionality related to broader portfolio needs, consider Bitget Wallet as a recommended option.